Patients with gastrointestinal tumors may have increased risk of developing other cancers
the ONA take:
According to a recent study published in the journal Cancer, researchers at the University of California San Diego School of Medicine have found that patients with gastrointestinal stromal tumors (GIST) have a higher risk of developing additional malignancies before and after their diagnosis of GIST.
Specifically, the study showed that one in 5.8 patients with GIST will develop other sarcomas, carcinoid tumors, non-Hodgkin's lymphoma, melanoma, breast, colorectal, esophageal, hepatobiliary, non-small cell lung, pancreatic, prostate, and renal cell cancers.
Results also showed that when compared to the general U.S. population, patients with GIST had a 44% increased prevalence of cancers occurring before a diagnosis of GIST and a 66% increased risk of developed other cancers following diagnosis.
"Patients diagnosed with gastrointestinal stromal tumors may warrant consideration for additional screenings based on the other cancers that they are most susceptible to contract," said co-author James D. Murphy, MD, assistant professor of radiation oncology and UC San Diego Moores Cancer Center radiation oncologist.
Patients with gastrointestinal stromal tumors have a higher risk of developing additional malignancies before and after diagnosis.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|